Morphosys agrees to buy cancer epigenetics specialist Constellation

German cancer and immunology firm Morphosys has agreed to buy US-based Constellation for $1.7 billion (£1.2 billion). The deal gives Morphosys access to Constellation’s pipeline of experimental drugs that aim to treat cancer by targeting epigenetic regulators to control gene expression.